Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer
Authors
Keywords
-
Journal
Thoracic Cancer
Volume 9, Issue 6, Pages 736-744
Publisher
Wiley
Online
2018-04-23
DOI
10.1111/1759-7714.12641
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Real-world Efficacy and Safety of Nivolumab for Advanced Non–Small-cell Lung Cancer: A Retrospective Multicenter Analysis
- (2018) Keigo Kobayashi et al. Clinical Lung Cancer
- Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals
- (2018) Kurt G. Tournoy et al. LUNG CANCER
- The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials
- (2017) Marco Donia et al. EUROPEAN JOURNAL OF CANCER
- Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Brain Metastases Working Group
- (2017) Nancy U. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
- (2017) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group
- (2017) Stuart M. Lichtman et al. JOURNAL OF CLINICAL ONCOLOGY
- Re-Evaluating Eligibility Criteria for Oncology Clinical Trials: Analysis of Investigational New Drug Applications in 2015
- (2017) Susan Jin et al. JOURNAL OF CLINICAL ONCOLOGY
- Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Minimum Age Working Group
- (2017) Lia Gore et al. JOURNAL OF CLINICAL ONCOLOGY
- Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research HIV Working Group
- (2017) Thomas S. Uldrick et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data
- (2017) Elizabeth Dudnik et al. LUNG CANCER
- Reevaluating Eligibility Criteria — Balancing Patient Protection and Participation in Oncology Trials
- (2017) Julia A. Beaver et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review of the ClinicalTrials.gov Trial Registry
- (2016) Caroline E. McCoach et al. Journal of Thoracic Oncology
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
- (2016) Sarah B Goldberg et al. LANCET ONCOLOGY
- Do participants in adjuvant breast cancer trials reflect the breast cancer patient population?
- (2015) Shaun Treweek et al. EUROPEAN JOURNAL OF CANCER
- Modernizing Eligibility Criteria for Molecularly Driven Trials
- (2015) Edward S. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of Survival Outcomes Among Cancer Patients Treated In and Out of Clinical Trials
- (2014) Joseph M. Unger et al. JNCI-Journal of the National Cancer Institute
- Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials
- (2013) D. Y. C. Heng et al. ANNALS OF ONCOLOGY
- Treatment outcome of advanced pancreatic cancer patients who are ineligible for a clinical trial
- (2013) Akira Ueda et al. OncoTargets and Therapy
- Recent trends in hepatitis B virus infection in the general Korean population
- (2013) Hyuck Kim et al. KOREAN JOURNAL OF INTERNAL MEDICINE
- Identifying Barriers Associated With Enrollment of Patients With Lung Cancer into Clinical Trials
- (2012) Leora Horn et al. Clinical Lung Cancer
- The eligibility of advanced non-small-cell lung cancer patients for targeted therapy clinical trials
- (2011) J. Clarey et al. ANNALS OF ONCOLOGY
- Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials
- (2009) Janette Vardy et al. BMC CANCER
- Including Persons With HIV Infection in Cancer Clinical Trials
- (2008) Govind C. Persad et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now